Most patients with mild COVID-19 infections produce antibodies that persist and protect them from reinfection for up to six months, a new study found. The antibodies’ ability to neutralize COVID-19 did not differ significantly from the first visit, which occurred three months after infection, to the second visit at the six-month mark.